ALK and neoplasm: Nonetheless, the circumvention of EMT-associated resistance to ALK–TKIs to restore the sensitivity of mesenchymal-type tumor cells to ALK–TKIs, remains an unmet need of targeted drug therapy in ALK-rearranged NSCLC.